All our actively recruiting studies are listed below.
All studies have an information sheet provided. These give further information on the study and details how to express your/your child's interest in taking part.
Each study has a unique email address so please make sure that you use the correct email for the correct study. The email addresses are provided in the respective information sheets.
Valneva Adolescent COVID study
Title: COV-COMPARE Immunogenicity of vaccine VLA2001 compared to AZD1222.
Valneva is now starting a Phase 3 clinical trial in adolescents aged 12-17 years to test a new candidate vaccine against COVID-19. Participation involves 3 dosing appointments and 4 follow-up appointments over the course of 12 months. Clinics are taking place over the next two weeks. Selected study participants will be compensated for their time and participation.
You can find out further information, and sign up, on the Valneva study website.
Title: Comparing COVID-19 Vaccine Schedule Combinations in adolescents (Com-COV3)
Bristol is looking for healthy teenage volunteers to participate in a COVID-19 vaccine trial. This study aims to compare two different vaccines at different doses as a boost. Young people aged 12-16 years who have received either 0 or 1 dose of the Pfizer vaccine to date may be eligible to participate.
• Young people aged 12 – 16 years are invited to receive COVID-19 vaccine
• We would give the first and second dose or the second dose only
• 5 or 6 visits over the next year
• 5 or 6 blood tests in total, taking place in University Hospitals Bristol and Weston NHS Foundation Trust
• Complete an online diary for around 2 months
For more details or to sign up, please visit the ComCov study website.
MET52 - Study to evaluate conjugate MenACYW vaccine in the UK infant schedule
Title: Study to evaluate conjugate MenACYW vaccine in the UK infant schedule
All babies normally receive a vaccine against meningitis type B (MenB) as part of the UK vaccination schedule. The new vaccine (MenACYW) aims to protect against additional meningitis types A, C, Y and W. It has been tested in more than 5,700 people - babies, children, adolescents, adults, and the elderly - and found to be safe and protective against meningococcal disease.
However, the MenACYW vaccine is ‘investigational’ meaning that it is not yet licensed for use in the UK or elsewhere.
The aim of the study is to show whether the immune response to the MenACYW vaccine is as strong as is needed, to protect against meningococcal disease, when it is given alongside the childhood vaccines given routinely in the United Kingdom (UK). The study is also looking at the safety of the MenACYW vaccine and the safety of the childhood vaccines when these are given together.
All participating babies will receive their routine vaccines as part of the study.
Please see the MET52 Patient Information Sheet (PDF, 255kB) if you would like to know more about taking part in this study.
Title: Quality of Life Effects of Chickenpox on Children and their Families.
There are 2 arms to this study. If you are eligible for the hospital arm you will be approached by one of our team.
Chickenpox is a very common childhood illness that almost all children catch before the age of 5 years. Most have a short illness with an itchy spotty rash but no long-lasting effects.
There are very effective vaccines against chickenpox that are used in many other countries. We don’t use them in the UK because we don’t have enough information of the effects of having chickenpox on children and their families.
The aim of our study is to find out the impact of chickenpox on families to help decide if we should use this vaccine in the future.
Please see the Chickenpox Information Sheet (PDF, 629kB) if you would like to know more about taking part in this study.
Avon Community-Acquired Pneumonia (AvonCAP)
Title: Avon Community-Acquired Pneumonia Surveillance Study: A Pan-pandemic Acute Lower Respiratory Tract Disease Surveillance Study
Avon CAP (Community-Acquired Pneumonia) study is an observational study taking place in several hospitals in the Avon area. As part of this study, we will be recording, how many adults are admitted to hospital each year due to respiratory illness.
We want to find out more about which bacteria and viruses cause disease and whether patients with underlying medical conditions are at increased risk of certain infections.
The study is coordinated by the Bristol Children’s Vaccine Centre (University of Bristol) and is funded by Pfizer. It has been approved by the Health Research Authority and East of England - Essex Research Ethics Committee.
For further information on this study, please visit AvonCAP's further study details pages.